当前位置： SCI文献检索 > CLINICAL PHARMACOKINETICS期刊下所有文献 > Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling.

Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling.

Abstract：

:The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to guide medication usage. This study aimed to provide a comprehensive review of drugs or diseases interacting with smoking, as presented in all US drug labelling. The 62,857 drug labels deposited in the FDA Online Label Repository were searched using the keywords 'smoke', 'smoker(s)', 'smoking', 'tobacco' and 'cigarette(s)' on 19 June 2014. The resultant records were refined to include only human prescription drug labelling, for manual examination. For 188 single-active-ingredient drugs and 36 multiple-active-ingredient drugs, the labelling was found to contain smoking-related information. The pharmacokinetics of 29 and 21 single-active-ingredient drugs were affected and unaffected, respectively, by smoking. For the remaining drugs, the provided information related to smoking affecting efficacy, safety or diseases but not pharmacokinetics. Depending on the nature of specific drugs, the perturbation in pharmacokinetic parameters in smokers ranged from 13 to 500%, in comparison with non-smokers. Dosage modifications in smokers are necessary for four drugs and may be necessary for six drugs, but are unnecessary for seven drugs although the pharmacokinetic parameters of four of them are affected by smoking. Cigarette smoking is a risk factor for 16 types of diseases or adverse drug reactions. For one single-active-ingredient contraceptive drug and 10 multiple-active-ingredient contraceptive drugs, a black box warning (the FDA's strongest safety warning) is included in the labelling for increased risks of heart attacks and strokes in female smokers, and "women are strongly advised not to smoke" when using these drugs. This study presents the first comprehensive overview of cigarette smoking interacting with drugs and/or diseases, as presented in US drug labelling.

journal_name

Clin Pharmacokinet

journal_title

Clinical pharmacokinetics

authors

Li H,Shi Q

doi

10.1007/s40262-015-0246-6

subject

Has Abstract

pub_date

2015-05-01 00:00:00

pages

493-501

issue

eissn

0312-5963

issn

1179-1926

journal_volume

pub_type

杂志文章,评审

在线工具

Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling.